The aim of this study was to present a case of transient myopia due to aripiprazole used in the treatment of depression. A 21-year-old female who was being treated for depression with 15 mg/day aripiprazol during 2 mounths. She normally uses-3.75 D glasses. She was admitted our outpatient clinic with sudden onset blurring of vision in both eyes in spite of uses glasses for about 3 days. Using of aripiprazole was observed in the patient's story. She was found to have myopia of−6.0 diopters in both eyes with measurement of otorefractometer; her visual acuity being 6/10 in both of eyes with her glasses. The other eye examination findings of the patient was normal. The drug was discontinued and patient was followed. One mount later on examination, the patient's visual acuity increased of 10/10 in both eyes. Follow the first day of the Alx values measured were 0.3 mm longer than 1 month after the measurement, the minimal difference between the other anterior segment findings were recorded. Although the specific mechanisms that cause acute myopia has not been fully revealed, it can be ciliary spasm, ciliary bodies effusion, peripheral uveal effusion and effects ofocular serotonergic intraneural fibers. We believe that it would be important for clinicians. They should keep in mind these conditions, when prescribing aripiprazole and need to inform patients about the side effects related to the eye.

The third generation antiepileptic, gabapentin, is a structural analogue of gamma aminobutyric acid (GABA), which is an important neurotransmitter of central nervous system. It is used to treat partial epilepsy, neuropathic pain, and movement disorders, as well as a variety of psychiatric conditions such as bipolar disorder, anxiety disorder, and alcohol addiction. Currently it is accepted to possess a potential for abuse and addiction. In this study, we present a case of a woman with depression who had been using a high dose gabapentin treatment for neuropathic pain due to spinal surgery performed 3 years before. Here, we highlight the withdrawal symptoms following the termination of gabapentin, and their treatment. The symptoms of varying severity in gabapentin withdrawal underline the importance of progressively decreasing the dose on a schedule of several months before ceasing the drug completely. Predisposing factors should be noted, and alternative treatment options like melatonin and mirtazapine should be considered.

ABSTRACT

No abstract

No abstract